Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$66.17 USD
-1.63 (-2.40%)
Updated May 23, 2024 04:00 PM ET
After-Market: $66.15 -0.02 (-0.03%) 7:58 PM ET
5-Strong Sell of 5 5
B Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GILD 66.17 -1.63(-2.40%)
Will GILD be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Gilead (GILD) Announces Positive Interim Results on PBC Drug
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Other News for GILD
Analysts’ Top Healthcare Picks: Scholar Rock Holding (SRRK), Gilead Sciences (GILD)
Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors
3 Biotech Stocks to Buy Now: May 2024
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
Gilead Sciences (GILD) Gets a Hold from Wells Fargo